

Patterns of Care in Medical Oncology

**Adjuvant and Neoadjuvant Therapy for
Triple-Negative Breast Cancer**

Clinical Scenario 10: A woman has a 1.0-cm, ER/PR/HER2-negative IDC.

Which of the following adjuvant chemotherapy treatments, if any, would you most likely recommend for this patient if her age and nodal status were:

	Node-negative		Node-positive	
	60 years old	75 years old	60 years old	75 years old
TC	57%	54%	17%	48%
AC → taxane	31%	7%	73%	40%
AC	5%	7%	3%	5%
CMF	0%	6%	1%	3%
Other	1%	0%	5%	1%
None	6%	26%	1%	3%

Clinical Scenario 11: A woman has a 3.4-cm, ER/PR/HER2-negative, node-negative IDC (3 sentinel nodes).

Which of the following adjuvant chemotherapy treatments, if any, would you most likely recommend in this case if the patient's age was:

	60 years old	75 years old
AC → taxane	57%	18%
TC	35%	65%
AC	4%	6%
CMF	0%	5%
Other	3%	0%
None	1%	6%

BEATRICE: A Phase III study of adjuvant bevacizumab therapy in triple-negative breast cancer

Protocol ID: BO20289

Target Accrual: 2,530

Eligibility

Operable triple-negative breast cancer without clinically significant cardiac history

R

```
graph LR; A[Eligibility: Operable triple-negative breast cancer without clinically significant cardiac history] --> B((R)); B --> C[Standard chemotherapy*]; B --> D[Standard chemotherapy* + bevacizumab x 1 y]
```

Standard chemotherapy*

Standard chemotherapy* + bevacizumab x 1 y

Primary Endpoint: Invasive disease-free survival

* Anthracycline ± taxane or taxane only

Clinical Scenario 12: A woman has a core biopsy as follows: 4-cm, ER/PR/HER2-negative, node-negative IDC (3 sentinel nodes). The patient wishes to undergo breast-conserving surgery, which will be difficult or impossible without shrinkage of the breast mass, so neoadjuvant therapy is being considered.

Which of the following chemotherapy treatments, if any, would you most likely recommend in this case if the patient's age was:

	60 years old	75 years old
AC → taxane	69%	22%
TC	16%	59%
AC	6%	8%
CMF	0%	4%
Other	7%	1%
None	2%	6%


Randomized Phase II 2 x 2 factorial trial of the addition of carboplatin with or without bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC in hormone receptor-poor/HER2-negative resectable breast cancer

Protocol ID: CALGB-40603

Target Accrual: 362

Eligibility

Stage II to III HER2-negative, ER/PR-negative or staining $\leq 10\%$ by IHC



Primary Endpoint: Pathologic complete response

P = paclitaxel


dd AC = dose-dense doxorubicin/cyclophosphamide

Cb = carboplatin

www.clinicaltrials.gov. Accessed March 2011.

Randomized Phase III neoadjuvant trial in triple-negative breast cancer evaluating nonanthracycline-containing chemotherapy and PARP inhibition with BSI-201 (iniparib)

Protocol ID: NSABP-B-48 (under development) **Target Accrual:** 540



Primary Endpoint: Pathologic complete response

WP = weekly paclitaxel 80 mg/m² IV

AC = doxorubicin 60 mg/m² IV + cyclophosphamide 600 mg/m² IV

TC = docetaxel 75 mg/m² IV + cyclophosphamide 600 mg/m² IV

CbG = carboplatin AUC of 2.0 IV + gemcitabine 1,000 mg/m² IV